Akebia Therapeutics Signs Multi-Year Commercial Supply Contract to Expand Access to Vafseo for Patients on Dialysis

Akebia Therapeutics, Inc. has signed a multi-year commercial contract with a leading provider of kidney care services, which will enable expanded access to Vafseo® (vadadustat) for patients on dialysis across the U.S. This contract allows physicians to prescribe Vafseo to patients on dialysis as clinically appropriate, with the aim to significantly broaden access to Vafseo among its physicians and for its more than 200,000 patients at dialysis centers across the U.S.